newsfilter
← Latest News
GlobeNewswire·

Paratek Pharmaceuticals' NUZYRA® Receives FDA Fast Track Designation for the Treatment of Pulmonary Nontuberculous Mycobacterial (NTM) Disease Caused by Mycobacterium Avium Complex (MAC) and Mycobacterium Abscessus (MAB)

-- Phase 2b Study in MAB Pulmonary Infections Ongoing and Enrolling as Planned -- Nonclinical Studies in MAC Initiating BOSTON, June 21, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) today announced the U.S. Food and Drug A